Beam's base editing works in the clinic; selling it is the next test

The technology

Beam Therapeutics uses base editing, a form of gene editing designed to correct single-letter changes in DNA. It has two kinds of programs. Risto-cel edits a patient's own blood stem cells outside the body to raise fetal hemoglobin in sickle cell disease. BEAM-302, BEAM-301 and BEAM-304 edit liver cells inside the body using lipid nanoparticles, for alpha-1 antitrypsin deficiency, glycogen storage disease Ia and phenylketonuria.

The clinical data so far are clean on biology. In BEACON, 31 risto-cel patients reached mean fetal hemoglobin above 60%, per the NEJM publication. At 60 mg, BEAM-302 cut mutant Z-AAT 84% and raised total AAT above the 11 micromolar protective level, according to ERS data.

The odds

Risto-cel is closest to market, with a BLA planned as early as year-end 2026, per the company. The BIO/Informa/QLS 2011 to 2020 study found that 90.6% of drugs reaching an NDA or BLA were approved, and 93.6% for rare diseases. The risk at this stage is less about approval and more about sales.

BEAM-302 is in a registrational cohort under a planned accelerated approval path. Phase 3 programs have a 52.4% chance of approval in the same study, and rare disease phase 3 programs move to filing 60.4% of the time. A biomarker endpoint that the drug already meets in phase 1/2 should improve those odds, but the plan rests on FDA feedback, not an approval decision. BEAM-304 and BEAM-301 are early. The base rate for a phase 1 program reaching approval is 7.9%, or 17.0% in rare disease.

The money

Beam held $1.15 billion in cash and investments at June 30, 2026, and lost $122.7 million in the second quarter. It says cash plus an expected additional $200 million from its Sixth Street facility funds operations into mid-2029.

That facility is $500 million of secured debt at about 10% interest, maturing in early 2033, with most of it tied to risto-cel milestones. It spares shareholders dilution now, but lenders have first-priority liens on substantially all assets. Revenue is small and lumpy: $0.49 million in the second quarter.

The risks

Risto-cel enters a market where Casgevy, from Vertex and CRISPR Therapeutics, is already sold and now approved for children as young as 2, per Vertex. Both need chemotherapy conditioning, which has held back uptake. Beam's BEAM-103 antibody, meant to replace chemotherapy, has only finished a healthy volunteer study.

For BEAM-302, one patient with liver disease had a transient grade 3 liver enzyme rise at 60 mg, according to the ERS release. Rival RNA editing drugs, such as Wave's WVE-006, which lifted Wave's shares 74% on early data, could compete in the same disease. All three liver programs share one delivery system, so a safety problem in one would raise questions for all.

Our read

Beam has moved from platform promise to two programs near registration, and the biology in both looks strong. The next 12 months are about execution: filing risto-cel on time, enrolling the BEAM-302 cohort, and turning a sickle cell market that has been slow for everyone into real sales. The hiring of Eric Foster as commercial chief shows the company is preparing for that. The balance sheet works, but it is tied to risto-cel milestones and secured debt, so a filing delay would hit both the clinic and the funding plan.